

CERTIFICATE OF ANALYSIS No.: 2021-5238

CLIENT

CIITECH Ltd, 2 Athenaeum Road
GB-N20 9AE London, United Kingdom

SAMPLE

Provacan CBD Paste 2500mg / 50%



Sample condition: SUITABLE
Sample ID: 2127019
Sample type: Paste
Batch No.: PA50021183A

Work order: 2021-105341
Analysis ID: 2021_156
Method ID: PHL_RPC_12C
Method SOP: MET-001

Sample received: 07/07/2021
Start of analysis: 07/07/2021
End of analysis: 08/07/2021
Analyst: Aleksander Jefim

CANNABINOID PROFILE	Concentration [% w/w]	Expanded uncertainty [% w/w]	Graphic presentation of relative cannabinoid concentration
CBDV - Cannabidivarin	7.58	0.38	
CBDA - Cannabidiolic acid	2.31	0.12	
CBGA - Cannabigerolic acid	0.066	0.020	
CBG - Cannabigerol	0.86	0.11	
CBD - Cannabidiol	47.7	2.4	
THCV - Tetrahydrocannabivarin	1.138	0.057	
CBN - Cannabinol	< LOQ	n/a	
CBC - Cannabichromene	0.0440	0.0097	
THC - Δ-9-Tetrahydrocannabinol	0.113	0.019	
THCA - Δ-9-Tetrahydrocannabinolic acid	0.0412	0.0091	
8-THC - Δ-8-Tetrahydrocannabinol *	< LOQ	n/a	
CBL - Cannabicyclol *	< LOQ	n/a	

The results marked by * relate to non-accredited activity.

Units and abbreviations: % w/w = weight percent, < LOQ = below the limit of quantitation (0.03 % w/w), ND = not detected, n/a = not available.


The results given herein apply only to the sample as received. Expanded Uncertainty was calculated using coverage factor k = 2, corresponding to a double standard uncertainty and characterizes the interval value in which it is possible to expect the real value with a probability of 95%. This is stated according to the ISO/IEC Guide 98-3.

Total or partial reproduction of this document is not allowed without the permit from PharmaHemp d.o.o. The document does not substitute any other legal document.

Date issued:

08/07/2021

Approved by:



mag. Marko Dragan
Analytical Laboratory Manager

Authorized by:



dr. Boštjan Jančar
Chief Technology Officer

End of Certificate